

S3 Table. Comparison according to HRR gene mutation (n=300)

Variable	Total (n=300)	ND and VUS (n=283)	LPV and PV (n=17)	p-value
Age (yr)				0.841 ^{a)}
Median (min-max)	65 (29-90)	65 (33-90)	64 (49-80)	
Sex				0.543 ^{b)}
Female	145 (48.3)	138 (48.8)	7 (41.2)	
Male	155 (51.7)	145 (51.2)	10 (58.8)	
Status				0.644 ^{b)}
Resectable	97 (32.3)	90 (31.8)	7 (41.2)	
Locally advanced	66 (22.0)	62 (21.9)	4 (23.5)	
Metastatic	137 (45.7)	131 (46.3)	6 (35.3)	
Tumor location				0.869 ^{b)}
Head or neck or uncinate process	147 (49.0)	139 (49.1)	8 (47.1)	
Body or tail	153 (51.0)	144 (50.9)	9 (52.9)	
Eastern Cooperative Oncology Group				0.650 ^{b)}
0	193 (64.3)	180 (63.6)	13 (76.5)	
1	87 (29.0)	83 (29.3)	4 (23.5)	
2, 3	20 (6.7)	20 (7.1)	0	
Family history				0.029 ^{b)}
None	165 (56.0)	159 (56.2)	5 (29.4)	
Present	135 (45.0)	124 (43.8)	12 (70.6)	
Pancreatic cancer family history				0.020 ^{c)}
None	280 (93.3)	267 (94.4)	13 (76.5)	
Present	20 (6.7)	16 (5.7)	4 (23.5)	
Pancreatic/breast/ovary cancer family history				0.036 ^{c)}
None	265 (88.3)	253 (89.4)	12 (70.6)	
Present	35 (11.7)	30 (10.6)	5 (29.4)	

Values are presented as number (%) unless otherwise indicated. HRR, homologous recombination repair; LPV, likely pathogenic variant; ND, not detected; PV, pathogenic variant; VUS, variants of uncertain significance. ^{a)}Wilcoxon rank sum test, ^{b)}Chi-squared test, ^{c)}Fisher's exact test.

References

1. Hu C, Hart SN, Polley EC, Gnanaolivu R, Shimelis H, Lee KY, et al. Association between inherited germline mutations in cancer predisposition genes and risk of pancreatic cancer. *JAMA*. 2018;319:2401-9.
2. Yin L, Wei J, Lu Z, Huang S, Gao H, Chen J, et al. Prevalence of germline sequence variations among patients with pancreatic cancer in China. *JAMA Netw Open*. 2022;5:e2148721.
3. Mizukami K, Iwasaki Y, Kawakami E, Hirata M, Kamatani Y, Matsuda K, et al. Genetic characterization of pancreatic cancer patients and prediction of carrier status of germline pathogenic variants in cancer-predisposing genes. *EBioMedicine*. 2020;60:103033.
4. Shindo K, Yu J, Suenaga M, Fesharakizadeh S, Cho C, Macgregor-Das A, et al. Deleterious germline mutations in patients with apparently sporadic pancreatic adenocarcinoma. *J Clin Oncol*. 2017;35:3382-90.
5. Chaffee KG, Oberg AL, McWilliams RR, Majithia N, Allen BA, Kidd J, et al. Prevalence of germline mutations in cancer genes among pancreatic cancer patients with a positive family history. *Genet Med*. 2018;20:119-27.
6. Wieme G, Kral J, Rosseel T, Zemankova P, Parton B, Vocka M, et al. Prevalence of germline pathogenic variants in cancer predisposing genes in Czech and Belgian pancreatic cancer patients. *Cancers (Basel)*. 2021;13:4430.
7. Yurgelun MB, Chittenden AB, Morales-Oyarvide V, Rubinson DA, Dunne RF, Kozak MM, et al. Germline cancer susceptibility gene variants, somatic second hits, and survival outcomes in patients with resected pancreatic cancer. *Genet Med*. 2019;21:213-23.